OnKure Therapeutics (OKUR)
OnKure Therapeutics on one page: short interest, daily short volume, fails to deliver, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq.
1.4M
Short interest
settlement 2026-10-15
2.5
Days to cover
-2.2 days vs prior
74.7%
Short share of volume
2026-11-02
748
Fails to deliver
settlement 2026-10-14
Thu 5 Nov
Next earnings
estimated date
-$1K
Insider flow, 90 days
0 buys, 2 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in OKUR is 1,385,534 shares, up 10,282 shares over the last month. Over the last 48 readings it ranged from 7,962 shares (13 March 2026) to 1,408,001 shares (15 January 2025). The latest reading sits at the top of that range. At the reported average volume of 544K shares a day that is 2.5 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/okur" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 1,385,534 | +13.2% | 543,501 | 2.55 |
| 2026-09-30 | 1,223,923 | -11.0% | 257,074 | 4.76 |
| 2026-09-15 | 1,375,252 | +4.0% | 148,214 | 9.28 |
| 2026-08-31 | 1,322,151 | +23.3% | 171,764 | 7.70 |
| 2026-08-14 | 1,071,973 | -9.7% | 134,805 | 7.95 |
| 2026-07-31 | 1,187,063 | +0.5% | 112,263 | 10.57 |
| 2026-07-15 | 1,181,591 | +34.5% | 204,025 | 5.79 |
| 2026-06-30 | 878,668 | +211.1% | 755,793 | 1.16 |
| 2026-06-15 | 282,400 | +20.2% | 379,774 | 1.00 |
| 2026-05-29 | 234,931 | +17.8% | 216,246 | 1.09 |
| 2026-05-15 | 199,392 | +92.9% | 142,174 | 1.40 |
| 2026-04-30 | 103,370 | +48.8% | 117,928 | 1.00 |
| 2026-04-15 | 69,494 | -57.6% | 198,708 | 1.00 |
| 2026-03-31 | 163,904 | +1958.6% | 786,389 | 1.00 |
| 2026-03-13 | 7,962 | -85.2% | 214,174 | 1.00 |
| 2026-02-27 | 53,751 | +61.0% | 107,155 | 1.00 |
| 2026-02-13 | 33,385 | +135.3% | 101,537 | 1.00 |
| 2026-01-30 | 14,187 | +43.6% | 68,471 | 1.00 |
| 2026-01-15 | 9,877 | -59.5% | 70,169 | 1.00 |
| 2025-12-31 | 24,394 | -53.1% | 103,510 | 1.00 |
| 2025-12-15 | 51,986 | +25.6% | 207,581 | 1.00 |
| 2025-11-28 | 41,393 | +9.9% | 100,735 | 1.00 |
| 2025-11-14 | 37,659 | -22.2% | 127,047 | 1.00 |
| 2025-10-31 | 48,380 | -25.7% | 161,875 | 1.00 |
| 2025-10-15 | 65,129 | -62.7% | 122,814 | 1.00 |
| 2025-09-30 | 174,585 | -9.6% | 52,526 | 3.32 |
| 2025-09-15 | 193,202 | -2.4% | 61,838 | 3.12 |
| 2025-08-29 | 197,866 | -13.6% | 60,126 | 3.29 |
| 2025-08-15 | 228,875 | +1.3% | 174,099 | 1.31 |
| 2025-07-31 | 225,946 | -7.6% | 79,189 | 2.85 |
| 2025-07-15 | 244,421 | -30.4% | 61,724 | 3.96 |
| 2025-06-30 | 351,182 | -31.5% | 71,532 | 4.91 |
| 2025-06-13 | 512,929 | -3.3% | 84,809 | 6.05 |
| 2025-05-30 | 530,270 | -5.3% | 260,107 | 2.04 |
| 2025-05-15 | 560,172 | -2.4% | 364,472 | 1.54 |
| 2025-04-30 | 574,041 | -50.3% | 83,882 | 6.84 |
| 2025-04-15 | 1,154,688 | +8.7% | 72,693 | 15.88 |
| 2025-03-31 | 1,062,398 | -1.0% | 23,962 | 44.34 |
| 2025-03-14 | 1,073,165 | -2.2% | 38,362 | 27.97 |
| 2025-02-28 | 1,097,765 | -0.1% | 32,604 | 33.67 |
| 2025-02-14 | 1,098,416 | -21.4% | 42,828 | 25.65 |
| 2025-01-31 | 1,397,975 | -0.7% | 124,710 | 11.21 |
| 2025-01-15 | 1,408,001 | +13.4% | 148,539 | 9.48 |
| 2024-12-31 | 1,241,990 | +0.1% | 208,642 | 5.95 |
| 2024-12-13 | 1,241,082 | +10.6% | 92,568 | 13.41 |
| 2024-11-29 | 1,121,953 | +10.4% | 49,495 | 22.67 |
| 2024-11-15 | 1,016,108 | +9.9% | 60,728 | 16.73 |
| 2024-10-31 | 924,624 | +33.3% | 61,645 | 15.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of OKUR volume is 74.7%, up 14.8 points over the last five sessions. Over the last 30 readings it ranged from 17.6% (28 September 2026) to 90.1% (30 October 2026). The latest reading is 23.6 points above the 30-session average of 51.2%, on 216K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 161K | 216K | 74.7% | 0 |
| 2026-10-30 | 102K | 113K | 90.1% | 0 |
| 2026-10-29 | 86K | 276K | 31.2% | 0 |
| 2026-10-28 | 59K | 109K | 53.8% | 0 |
| 2026-10-27 | 76K | 97K | 78.9% | 0 |
| 2026-10-26 | 47K | 79K | 59.9% | 0 |
| 2026-10-23 | 58K | 103K | 56.2% | 0 |
| 2026-10-22 | 45K | 86K | 52.5% | 0 |
| 2026-10-21 | 49K | 77K | 64.4% | 0 |
| 2026-10-20 | 55K | 107K | 51.2% | 0 |
| 2026-10-19 | 165K | 252K | 65.2% | 0 |
| 2026-10-16 | 122K | 258K | 47.4% | 0 |
| 2026-10-15 | 152K | 202K | 75.0% | 1,750 |
| 2026-10-14 | 162K | 190K | 85.2% | 0 |
| 2026-10-13 | 117K | 151K | 77.2% | 0 |
| 2026-10-12 | 52K | 85K | 60.7% | 0 |
| 2026-10-09 | 77K | 287K | 26.7% | 0 |
| 2026-10-08 | 76K | 315K | 24.3% | 0 |
| 2026-10-07 | 39K | 119K | 32.9% | 0 |
| 2026-10-06 | 59K | 205K | 28.6% | 0 |
| 2026-10-05 | 102K | 376K | 27.1% | 0 |
| 2026-10-02 | 86K | 251K | 34.4% | 0 |
| 2026-10-01 | 735K | 1.2M | 60.6% | 0 |
| 2026-09-30 | 96K | 538K | 17.8% | 4,495 |
| 2026-09-29 | 51K | 214K | 23.9% | 4,740 |
| 2026-09-28 | 54K | 305K | 17.6% | 588 |
| 2026-09-25 | 29K | 41K | 71.2% | 0 |
| 2026-09-24 | 27K | 89K | 30.6% | 0 |
| 2026-09-23 | 38K | 70K | 54.2% | 0 |
| 2026-09-22 | 54K | 88K | 61.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 14 October 2026, the fails-to-deliver balance in OKUR is 748 shares, up 198 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (28 August 2026) to 182,052 shares (24 April 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-14 | 748 | $2.35 | $2K |
| 2026-10-13 | 550 | $2.42 | $1K |
| 2026-10-09 | 952 | $2.30 | $2K |
| 2026-10-07 | 745 | $2.46 | $2K |
| 2026-10-06 | 715 | $2.63 | $2K |
| 2026-10-05 | 1,280 | $2.56 | $3K |
| 2026-10-02 | 1,786 | $2.54 | $5K |
| 2026-10-01 | 1,610 | $2.73 | $4K |
| 2026-09-24 | 3,960 | $2.94 | $12K |
| 2026-09-17 | 389 | $2.88 | $1K |
| 2026-09-16 | 1,636 | $2.93 | $5K |
| 2026-08-31 | 2 | $3.79 | $8 |
| 2026-08-28 | 2 | $3.83 | $8 |
| 2026-08-21 | 46 | $3.93 | $181 |
| 2026-08-20 | 90 | $4.08 | $367 |
| 2026-08-11 | 557 | $4.06 | $2K |
| 2026-08-05 | 2,984 | $4.10 | $12K |
| 2026-06-24 | 45 | $4.20 | $189 |
| 2026-06-23 | 625 | $4.44 | $3K |
| 2026-06-22 | 1,322 | $4.48 | $6K |
| 2026-06-15 | 232 | $4.20 | $974 |
| 2026-06-05 | 553 | $4.30 | $2K |
| 2026-05-15 | 1,514 | $3.34 | $5K |
| 2026-04-27 | 61,511 | $4.80 | $295K |
| 2026-04-24 | 182,052 | $4.90 | $892K |
| 2026-04-22 | 1,427 | $4.88 | $7K |
| 2026-04-16 | 946 | $4.51 | $4K |
| 2026-04-10 | 11,554 | $4.28 | $49K |
| 2026-03-31 | 10 | $3.79 | $38 |
| 2026-03-30 | 49,352 | $3.99 | $197K |
Insider trades
SEC Form 4, newest first. JSONInsiders at OKUR reported 2 open-market sells worth $1K in the last 90 days and no open-market buys. Latest filing: Leverone Jason A. (Chief Financial Officer) on 2026-09-21.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-21 | Leverone Jason A. | Chief Financial Officer | Sell | 302 | $2.97 | $898 | 19K |
| 2026-09-21 | Saccomano Nicholas A | President and CEO | Sell | 87 | $2.97 | $259 | 11K |
| 2026-06-22 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $4.40 | $1K | 19K |
| 2026-06-22 | Saccomano Nicholas A | President and CEO | Sell | 86 | $4.40 | $378 | 11K |
| 2026-03-23 | Saccomano Nicholas A | President and CEO | Sell | 86 | $4.16 | $357 | 7K |
| 2026-03-23 | Leverone Jason A. | Chief Financial Officer | Sell | 301 | $4.16 | $1K | 16K |
| 2025-12-31 | Mathers Edward T | Director | Grant | 4K | $0.00 | $0 | 15K |
| 2025-12-31 | Manke Isaac | Director | Grant | 5K | $0.00 | $0 | 21K |
| 2025-12-22 | Saccomano Nicholas A | President and CEO | Sell | 87 | $2.97 | $258 | 7K |
| 2025-12-22 | Leverone Jason A. | Chief Financial Officer | Sell | 302 | $2.97 | $896 | 16K |
| 2025-09-30 | Mathers Edward T | Director | Grant | 4K | $0.00 | $0 | 11K |
| 2025-09-30 | Manke Isaac | Director | Grant | 6K | $0.00 | $0 | 15K |
| 2025-09-22 | Saccomano Nicholas A | President and CEO | Sell | 88 | $2.62 | $231 | 4K |
| 2025-09-22 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $2.62 | $795 | 13K |
| 2025-06-30 | Mathers Edward T | Director | Grant | 5K | $0.00 | $0 | 7K |
| 2025-06-30 | Manke Isaac | Director | Grant | 6K | $0.00 | $0 | 10K |
| 2025-06-23 | Saccomano Nicholas A | President and CEO | Sell | 88 | $2.38 | $210 | 4K |
| 2025-06-23 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $2.38 | $722 | 13K |
| 2025-05-15 | ACORN CAPITAL ADVISORS GP, LLC | TenPercentOwner | Buy | 270K | $1.85 | $500K | 1.7M |
| 2025-05-15 | ACORN CAPITAL ADVISORS GP, LLC | TenPercentOwner | Buy | 1.1M | $1.85 | $2.1M | 1.1M |
| 2025-05-15 | Cormorant Private Healthcare Fund III LP | Other | Sell | 1.8M | $1.85 | $3.4M | 0 |
| 2025-05-12 | Cormorant Global Healthcare Master Fund, LP | TenPercentOwner | Sell | 24K | $1.99 | $48K | 1.8M |
| 2025-04-07 | Leverone Jason A. | Chief Financial Officer | Sell | 2K | $2.67 | $5K | 13K |
| 2025-04-07 | Saccomano Nicholas A | President and CEO | Sell | 516 | $2.67 | $1K | 4K |
| 2025-04-04 | Leverone Jason A. | Chief Financial Officer | Sell | 1K | $3.33 | $4K | 15K |
| 2025-04-04 | Saccomano Nicholas A | President and CEO | Sell | 358 | $3.33 | $1K | 4K |
| 2025-03-31 | Manke Isaac | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2025-03-31 | Mathers Edward T | Director | Grant | 3K | $0.00 | $0 | 3K |
| 2024-10-07 | Leonard Braden Michael | Other | Other transaction | 346K | price not stated in the filing | not stated | 346K |
| 2024-10-07 | Leonard Braden Michael | Other | Other transaction | 102K | price not stated in the filing | not stated | 102K |
| 2024-10-04 | Carruthers R Michael | Director | Grant | 874 | price not stated in the filing | not stated | 874 |
| 2024-10-04 | Carruthers R Michael | Director | Grant | 4K | price not stated in the filing | not stated | 5K |
| 2024-10-04 | Leverone Jason A. | Chief Financial Officer | Grant | 16K | price not stated in the filing | not stated | 16K |
| 2024-10-04 | Saccomano Nicholas A | President and CEO | Grant | 5K | price not stated in the filing | not stated | 5K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first, 50 of 51 shown. JSON25 holders report 5% or more of OKUR in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is AI Biotechnology LLC at 20.0% of the class (9,091,532 shares), filed 2026-04-07 for an event on 2026-03-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-10-07 | 13G | Matthew D. Perryparent holding company, individual | 2.7M | 6.7% | 2026-10-01 |
| 2026-10-07 | 13G | Coastlands Capital LLCparent holding company, other entity | 2.7M | 6.7% | 2026-10-01 |
| 2026-10-07 | 13G | Coastlands Capital GP LLCother entity | 2.7M | 6.7% | 2026-10-01 |
| 2026-10-07 | 13G | Coastlands Capital LPinvestment adviser, partnership | 2.7M | 6.7% | 2026-10-01 |
| 2026-10-07 | 13G | Coastlands Capital Partners LPpartnership | 2.7M | 6.7% | 2026-10-01 |
| 2026-08-14 | 13G/Ano. 1 | Ortav Yehudaiindividual | 1.4M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Trails Edge Capital Partners, LPinvestment adviser, partnership | 1.4M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Trails Edge Biotechnology Master Fund, LPpartnership | 1.4M | 3.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | Daniel Schneebergerparent holding company, individual | 2.2M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | ADAR1 Capital Management, LLCinvestment adviser, other entity | 2.2M | 5.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 2 | ADAR1 Capital Management GP, LLCother entity | 1.8M | 4.5% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BVF PARTNERS L P/ILinvestment adviser, partnership | 3.2M | 8.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BVF INC/ILcorporation | 3.2M | 8.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | LAMPERT MARK Nindividual | 3.2M | 8.0% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BVF GP HOLDINGS LLCother entity | 3.0M | 7.3% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BVF I GP LLCother entity | 1.7M | 4.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND L Ppartnership | 1.7M | 4.1% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BVF II GP LLCother entity | 1.3M | 3.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BIOTECHNOLOGY VALUE FUND II LPpartnership | 1.3M | 3.2% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | BVF Partners OS Ltd.corporation | 226K | 0.6% | 2026-06-30 |
| 2026-08-14 | 13G/Ano. 1 | Biotechnology Value Trading Fund OS LPpartnership | 226K | 0.6% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | Prosight Management, LPinvestment adviser | 979K | 2.4% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | Prosight Partners, LLCother entity | 979K | 2.4% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | W. Lawrence Hawkinsparent holding company, individual | 979K | 2.4% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | Prosight Plus Fund, LPpartnership | 220K | 0.5% | 2026-06-30 |
| 2026-08-10 | 13G/Ano. 1 | Prosight Fund, LPpartnership | 46K | 0.1% | 2026-06-30 |
| 2026-04-07 | 13G | RA Capital Management, L.P.investment adviser, partnership | 4.0M | 9.9% | 2026-03-31 |
| 2026-04-07 | 13G | RA Capital Healthcare Fund, L.P.partnership | 4.0M | 9.9% | 2026-03-31 |
| 2026-04-07 | 13G | Rajeev Shahparent holding company, individual | 4.0M | 9.9% | 2026-03-31 |
| 2026-04-07 | 13G | Peter Kolchinskyparent holding company, individual | 4.0M | 9.9% | 2026-03-31 |
| 2026-04-07 | 13D | AI Biotechnology LLCother entity | 9.1M | 20.0% | 2026-03-31 |
| 2026-04-07 | 13D | Access Industries Holdings LLCother entity | 9.1M | 20.0% | 2026-03-31 |
| 2026-04-07 | 13D | Access Industries Management, LLCother entity | 9.1M | 20.0% | 2026-03-31 |
| 2026-04-07 | 13D | Len Blavatnikindividual | 9.1M | 20.0% | 2026-03-31 |
| 2026-04-07 | 13G | StepStone Group LPpartnership | 2.7M | 6.6% | 2026-03-31 |
| 2026-04-07 | 13G | StepStone Master G, L.P.partnership | 2.7M | 6.6% | 2026-03-31 |
| 2026-04-07 | 13G | StepStone VC MI-G GP, LLCother entity | 2.7M | 6.6% | 2026-03-31 |
| 2026-04-01 | 13G | Anders Hoveindividual | 3.9M | 9.5% | 2026-03-27 |
| 2026-04-01 | 13G | ACORN BIOVENTURES 2, L.P.partnership | 2.1M | 5.0% | 2026-03-27 |
| 2026-04-01 | 13G | Acorn Capital Advisors GP 2, LLCother entity | 2.1M | 5.0% | 2026-03-27 |
| 2026-04-01 | 13G | ACORN BIOVENTURES, L.P.partnership | 1.9M | 4.5% | 2026-03-27 |
| 2026-04-01 | 13G | ACORN CAPITAL ADVISORS GP, LLCother entity | 1.9M | 4.5% | 2026-03-27 |
| 2026-02-17 | 13G/Ano. 1 | Kenneth Griffinparent holding company, individual | 223K | 1.7% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Citadel Securities GP LLCparent holding company, other entity | 174K | 1.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Citadel Securities LLCbroker-dealer, other entity | 174K | 1.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Citadel Securities Group LPparent holding company, partnership | 174K | 1.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Citadel Advisors Holdings LPparent holding company, partnership | 49K | 0.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Citadel Advisors LLCinvestment adviser, parent holding company, other entity | 49K | 0.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Citadel GP LLCparent holding company, other entity | 49K | 0.4% | 2025-12-31 |
| 2026-02-17 | 13G/Ano. 1 | Highbridge Capital Management, LLCinvestment adviser, other entity | 542K | 4.2% | 2025-12-31 |
13F holders
Tracked managers holding OKUR at their latest 13F. JSON3 of the 30 tracked managers held OKUR at their latest 13F, $7.5M in total at quarter-end prices. Citadel Advisors is the largest at $5.4M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Citadel Advisors | 2026-06-30 | 1.2M | $5.4M | 0.00% | +1.1M |
| Renaissance Technologies | 2026-06-30 | 359K | $1.6M | 0.00% | -19K |
| Two Sigma Investments | 2026-06-30 | 109K | $496K | 0.00% | +85K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
OnKure Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows OnKure Therapeutics (OKUR), SEC CIK 1637715, listed on Nasdaq. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-14.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-10-07.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-04.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-21.JSON and CSV
- Company record
- EDGAR filing index for CIK 1637715Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
- SYRESpyre Therapeutics
- SYYSysco
- TAT&T
- TAPMolson Coors
- TCOMTrip.com Group
- TDToronto-Dominion Bank
- TDGTransDigm Group
- TDYTeledyne Technologies
Datasets
Frequently Asked Questions
How much of OKUR is sold short?
1,385,534 shares were held short at the 2026-10-15 settlement, 2.5 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is OKUR's daily short volume?
On 2026-11-02, 161,262 of the 215,776 OKUR shares reported to FINRA were sold short, 74.7% of the day's reported volume. Short volume is a flow for one day, not a position.
Does OKUR have fails to deliver?
The SEC's latest file shows 748 OKUR shares failed to deliver at settlement 2026-10-14. Fails are reported per settlement date and published twice a month with a lag.
Are OKUR insiders buying or selling?
Insiders at OKUR reported 2 open-market sells worth $1K in the last 90 days and no open-market buys. Latest filing: Leverone Jason A. (Chief Financial Officer) on 2026-09-21.
Who owns 5% or more of OKUR?
25 holders report 5% or more of OKUR in their latest filing, 4 on Schedule 13D (active intent). The largest reported stake is AI Biotechnology LLC at 20.0% of the class (9,091,532 shares), filed 2026-04-07 for an event on 2026-03-31.
Which tracked 13F managers own OKUR?
3 of the 30 tracked 13F managers held OKUR shares at their latest filing, $7.5M in all. The largest: Ken Griffin's Citadel Advisors (1.2M shares, $5.4M), Renaissance Technologies (359K shares, $1.6M), Two Sigma Investments (109K shares, $496K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.